Many income investors gravitate toward stocks that offer up the highest dividend yields. In the healthcare sector, that typically means they buy big pharmaceutical stocks, since large-cap drug companies tend to offer some of its highest yields. However, the best pharmaceutical stocks often aren't the top yielding ones. After all, a high yield is commonly the result of a falling stock price, and a signal that a company is in danger of needing to reduce or eliminate its quarterly payout.
To see this principle in action, let's take a look at seven pharmaceutical stocks with market caps of at least $2 billion and rank them by their current dividend yield. Doing so produces a list that looks like this:
|Merck & Co.||MRK||3.20%|
If the only metric that you used to make investment decisions was the dividend yield, then you would probably conclude that AstraZeneca (NYSE:AZN) and GlaxoSmithKline PLC (NYSE:GSK) were the best buys from this group. After all, both of those companies offer dividend yields of more than 5%, which is more than double that of the S&P 500 index.
However, investing wisely is rarely about trying to maximize a single metric, and that's especially true with the dividend yield. There are plenty of other factors you need to consider before you buy shares in any company, such as valuation, growth prospects, and risk.
To drive that last point home, let's have another look at that same list of companies, but with a small twist. This time around, I'll add in two simple valuation metrics and what kind of profit growth analysts are expecting from the company over the next five years.
Here's what that expanded table looks like:
|Company||Ticker||Dividend Yield||Trailing P/E Ratio||Forward P/E Ratio||
Estimated 5-Year EPS Growth Rate
|Merck & Co.||MRK||3.20%||35||15||3.3%|
As you can see, adding in just a few other metrics starts to give potential investors a more complete picture. Yes, AstraZeneca and GlaxoSmithKline offer up the highest dividend yields from the group, but they also have the worst estimated growth prospects. That's a big reason why the markets are shunning those stocks, which has pushed up their dividend yields.
Pharmaceutical stocks to avoid
GlaxoSmithKline has been struggling recently because one of its best-selling drugs, Advair, has seen all of its key patents expire. GlaxoSmithKline has been working on breathing new life into its respiratory franchise with the release of Breo Ellipta and Anoro Ellipta, but sales of each struggled out of the gate. Things have picked up recently, but the company is fighting an uphill battle as it tries to replace the lost revenue from Advair. That's why the markets are not exactly predicting a rosy future for this company's bottom line over the next few years, which I think makes this one a stock to avoid.
The story with AstraZeneca is quite similar. Patent expirations have taken a major toll on the company's top line as sales have been in decline since peaking in 2010. The future doesn't look any better, because it lost patent protection on Nexium last year, and it's slated to lose patent protection on another key drug, Crestor, later this year. That's a big reason why investors have pushed this company's yield up so high -- because profits are expected to head in the wrong direction for several more years. And it's reason enough for me to want to avoid this stock.
In fact, I'd suggest that investors should avoid any drugmaker from this list that is not going to grow its bottom line by at least 5% over the coming years. Why bother investing in slow-growth stocks if there are better opportunities out there with similar valuation multiples? That immediately removes AstraZeneca, GlaxoSmithKline, Novartis, and Merck & Co. from our list of stocks to consider.
That leaves us with three potential investable companies: Sanofi (NYSE:SNY), AbbVie (NYSE:ABBV), and Pfizer (NYSE:PFE). Let's take a closer look at each to see if we can figure out if any of them are worth buying.
Sanofi is a questionable company to invest in right now. The company has been plagued with leadership issues and has made a few high-profile bad bets. That's a big reason why its stock has been stuck in the mud for years and why it remains in turnaround mode.
However, its near-term future looks questionable to me since its cash-cow diabetes drug Lantus is facing some serious challenges. To help combat the potential sales decline of Lantus, Sanofi expects to launch six new major drugs between now and 2020. That's exciting, but it also represents a real risk that the launches may not go according to plan, which could put its long-term growth targets in jeopardy. In addition, the company is planning on using layoffs to help it reach its profit targets, which I find uninspiring. That makes me want to stay away from this company's stock for the time being.
Two pharmaceutical stocks to buy
The metrics on the table above suggest that AbbVie's stock could be a smart choice. Not only does it offer up a yield of 3.74%, but analysts are also projecting profit growth of more than 16% over the next five years. That's a compelling combination, so what does AbbVie have going for it that's allowing it to grow so fast?
The answer there is Humira, its best-selling anti-inflammation drug that is approved to treat a wide range of indications. AbbVie sold more than $14 billion worth of Humira last year, which was up a huge 19% over the prior year when you adjust for currency fluctuations. AbbVie's management team believes that Humira will continue to grow quickly over the coming years, and when you add in the contributions of its other fast-growing drugs -- like its cancer drug, Imbruvica, and its hepatitis C cure, Viekira Pak -- this company's growth prospects look bright. That's why management has stuck its neck out and projected double-digit rates between now and 2020. If true, that makes AbbVie's stock a buy in my book, especially with shares trading around 11 times next year's earnings.
Finally, let's look at Pfizer. A few years ago Pfizer was the poster child for patent risk. Sales plunged in the wake of it losing patent protection on Lipitor, its blockbuster cholesterol-busting drug. However, that loss forced the company to undergo a massive restructuring, which is now starting to pay off.
Pfizer is now positioned for strong growth over the coming years, thanks in large part to three big trends. First, it's going to be a major player in the shift toward biologic drugs thanks to its $17 billion acquisition of Hospira last year. Second, its pneumococcal vaccine, Prevnar 13, has become a cash cow, and Europe offers strong growth prospects. Third, its recently launched best cancer drug, Ibrance, is already on pace for megablockbuster status. Add in a solid pipeline and I think that the company's forward price-to-earnings ratio of only 13 makes this stock a buy.
There's more to healthcare investing than just a big dividend yield
As you can see, it's well worth the time to do a bit more research on a stock before you hit the "Buy" button. I'm a big fan of high dividend yields, but only when the companies behind the stocks also offers up solid long-term growth prospects. If they don't, then you are probably better off staying far away.
Brian Feroldi has no position in any stocks mentioned. Like this article? Follow him on Twitter where he goes by the handle @Longtermmind-set or connect with him on LinkedIn to see more articles like this.
The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.